We audited the marketing at Amaros AI
AI platform accelerating clinical trials in ophthalmology
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
481 LinkedIn followers suggests minimal founder visibility in a niche where thought leadership drives trial recruitment and investigator partnerships
14-person team focused on product with likely underdeveloped outbound motion to CROs, trial sites, and pharma sponsors running ophthalmology studies
Post-Series A funding creates urgency to demonstrate traction with trial networks and pharma, but visibility among key decision-makers appears limited
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiAmaros AI's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Early-stage biotech with strong product positioning but underdeveloped marketing infrastructure across acquisition and expansion channels
Clinical trial software search intent is high-volume but competitive. No evidence of owned content targeting CROs, trial sponsors, or ophthalmology research centers
MH-1: SEO agent builds content around trial acceleration benchmarks, ophthalmology-specific compliance, and patient recruitment workflows
LLM queries about 'clinical trial software' and 'ophthalmology research platforms' show no presence. Biotech buyers increasingly ask AI assistants for vendor discovery
MH-1: AEO agent optimizes for AI queries about trial efficiency, ophthalmology data management, and regulatory compliance in clinical research
B2B biotech buying requires high-touch targeting of CROs, pharma R&D departments, and trial networks. No visible paid presence in those channels
MH-1: Paid agent runs LinkedIn and Google campaigns targeting trial sponsors, contract research organizations, and ophthalmology research investigators
Co-founders have strong credentials but minimal public thought leadership. Opportunity to establish authority in trial efficiency and ophthalmology innovation
MH-1: Content agent builds founder narratives around trial speed, cost reduction, and patient experience improvements specific to eye research
Post-Series A positioning suggests customer acquisition focus but no visible customer success or expansion messaging to existing trial networks
MH-1: Lifecycle agent maps customer segments, builds case studies from trial sponsors, and creates expansion plays for multi-site deployments
Top Growth Opportunities
Pharma companies conducting ophthalmology trials are actively evaluating efficiency solutions. Direct outreach to trial sponsors and contract research organizations drives near-term pipeline
Outbound agent builds targeted campaigns for ophthalmology trial sponsors, identifies key decision-makers at major CROs, and sequences personalized trial acceleration case studies
Ophthalmology research investigators are fragmented but networked through professional societies. Positioning as trial recruitment and efficiency platform unlocks investigator-led adoption
Content and SEO agents create investigator-focused resources on patient recruitment, compliance automation, and trial timeline acceleration in ophthalmology
Buyers now ask LLMs and AI chatbots for clinical trial software recommendations. Absence from these queries means missing procurement conversations before RFPs are issued
AEO agent ensures platform ranks in AI-generated answers for trial efficiency, ophthalmology research, and regulatory compliance queries
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Amaros AI. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Amaros AI's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Amaros AI's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Amaros AI's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Amaros AI from week 1.
AEO agent optimizes for LLM queries about clinical trial platforms, ophthalmology research software, and trial efficiency solutions to appear in AI-generated recommendations for biotech procurement teams
Founder LinkedIn agent builds Vartan and Ben's profiles as thought leaders in ophthalmology innovation and trial acceleration, driving investigator and sponsor discovery through founder networks
Paid acquisition agent targets trial sponsors, CROs, and pharma R&D departments on LinkedIn and Google with ophthalmology trial efficiency messaging, mapping prospect segments by trial phase and company size
Lifecycle agent maps customer segments from early trial sponsors, automates expansion sequences for multi-site deployments, and surfaces case study opportunities to build social proof
Competitive watch agent monitors trial software alternatives and pharma procurement trends to identify positioning gaps and emerging buyer needs in ophthalmology research
Pipeline intelligence agent identifies sponsored ophthalmology trials, tracks CRO hiring signals, and surfaces high-intent prospects running multi-site studies that require efficiency platforms
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Amaros AI's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focuses on audience mapping and quick wins. We identify your highest-value buyer segments within pharma sponsors and CROs, launch founder thought leadership on LinkedIn to build investigator awareness, establish SEO and AEO foundations for trial software keywords, and run initial outbound campaigns to trial networks. Parallel work surfaces customer case study opportunities to build proof points. By day 90 you'll have measurable traction in pipeline generation and visibility signals across all channels.
How does AEO help clinical trial software get discovered
Biotech buyers increasingly ask AI assistants like ChatGPT and Claude for clinical trial platform recommendations before issuing RFPs. AEO ensures your platform appears in those AI-generated answers by optimizing web content for the specific queries procurement teams ask LLMs. This captures buyers earlier in their decision process, before traditional search or paid channels activate.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Amaros AI specifically.
How is this page personalized for Amaros AI?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Amaros AI's current marketing. This is a live demo of MH-1's capabilities.
Accelerate clinical trial visibility to pharma sponsors and CROs
The system gets smarter every cycle. Let's talk about building it for Amaros AI.
Book a Strategy CallMonth-to-month. Cancel anytime.